UNASSIGNED: The purpose of our study is to determine the outcome of @entity1 with systemic @entity1893 presenting with neurologic localization at diagnosis, as well as the impact of consolidation in terms of high dose therapy followed by autologous stem cell transplantation on outcome in this population. Newly diagnosed @entity1893 @entity1 with concomitant systemic and neurologic involvement at diagnosis were included in this study. @entity1 were retrieved from the database of the participating centers of Lymphoma Study Association and Lymphome Oculo-cerebral network. Sixty @entity1 (37 males; 25 females) were included. Median age was 61 years (23-85). Histological subtype was mainly diffuse large @entity1892 (n=54; 90%). The International prognostic index was > 2 in 41 (72%) @entity1 . @entity880 dehydrogenase level was elevated in 35 (60%) @entity1 . Median number of extranodal sites was 2 (1-5) and bone marrow involvement was documented in 25 (45%) @entity1 . Central nervous system involvement alone was documented in 48 @entity1 . Paravertebral involvement with epidural mass and @entity1745 and positive cerebrospinal fluid were present in 7 @entity1 . Five @entity1 had both central nervous system and epidural involvement. First-line chemotherapy was mainly @entity5948 -based (88%) plus high dose @entity1499 (74%) with or without @entity2592 . High dose therapy followed by autologous stem cell transplantation was performed as consolidation treatment in 19 @entity1 . For the whole population, overall response rate after induction chemotherapy was 76% (complete remission=68%; partial remission=8%). Three-year progression free survival and overall survival were 42+/-7 % and 44+/-7% respectively. For @entity1 less than 66 years-old, consolidation strategy using high dose therapy followed by autologous stem cell transplantation positively impacted 3-year overall survival and progression free survival (73% vs 28%; p=0.008) and (73% vs 21%; p=0.003) respectively. In multivariate analysis and for the whole group of @entity1 , high dose therapy had a positive impact on 3-year overall survival [p=0.003; HR=0.20 (0.07-0.59)] and progression free survival by [p=0.001; HR=0.17 (0.06-0.49)] respectively. This also remained true in the subgroup of @entity1 under 66 years old in CR after induction therapy for OS [p=0.008; HR=0.22 (0.07-0.67)] and progression free survival [p=0.002; HR=0.17 (0.05-0.54)] In conclusion, @entity1893 prognosis with concomitant systemic and neurologic involvement at diagnosis is poor with a high risk of relapse when treated with conventional chemotherapies alone. This retrospective study supports the feasibility and the potential benefit of a consolidative strategy with high dose therapy followed by autologous stem cell transplantation in this subset of @entity1 . This strategy and the best intensive chemotherapy regimen remains to be validated in prospective trials.

Concomitant Systemic and Central Nervous System XXXX : The Role of Consolidation in terms of High Dose Therapy and Autologous Stem Cell Transplantation. A 60-case Retrospective Study from LYSA and the LOC network.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5948 :: ('D018943', 'Chemical') :: ['anthracycline'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphoma'] @entity1745 :: ('MESH:D013117', 'Disease') :: ['cord compression'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['Lactate'] @entity1893 :: ('MESH:D008228', 'Disease') :: ['non-Hodgkin lymphoma', 'non-Hodgkin Lymphoma'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity1893 :: (MESH:D008228,Disease) :: ['Non-Hodgkin's Lymphoma']
